An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2010/2011, in an Adult and Elderly Population

NCT01157702 Phase 3 COMPLETED

The purpose of the study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season for yearly licensing application.

Details

Lead sponsor	Alachua Government Services, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	110
Start date	2010-07
Completion	2010-08

Conditions

• Influenza
• Seasonal Influenza

Interventions

• Inactivated influenza vaccine (split virus, Vero cell-derived)

Primary outcomes

• To assess the immunogenicity to each of the three antigens contained in a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season in an adult and elderly population — 1 month

Countries

Austria